NCT07229651

Metformin in Parkinson Disease

Safety and Efficacy of Metformin in Patients With Parkinson Disaese

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Levodopa Carbidopa	Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
DRUG	Metformin	Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.

Timeline

• Start date: 2025-11-10
• Primary completion: 2026-11-20
• Completion: 2027-09-20
• First posted: 2025-11-17
• Last updated: 2025-11-21

Locations

1 site across 1 country: Egypt